Patients and Doctors: Bridging the Divide

Size: px
Start display at page:

Download "Patients and Doctors: Bridging the Divide"

Transcription

1 Patients and Doctors: Bridging the Divide Thomas Ullman, M.D. Director, Center for IBD The Mount Sinai IBD Center Chair, Professional Education, CCFA

2 What we d like to avoid....

3 Differing Points of View: Overview Cause of PSC/IBD Prescription Medicines Alternative Medicines Diet Internet and Information about PSC/IBD

4 Epidemiology Of Crohn s Disease Temporal Trends In Crohn s Disease, Olmsted County, Adjusted Incidence Per 100,000 Person-Years Male Female Total Year Of Diagnosis Prevalence: cases per 100, ~ ,000 cases in US 3 1. Ingle et al. Gastroenterology. 2007;132(4 Suppl 2):A Presented at Digestive Disease Week; May 19-24, # Bernstein et al. Am J Gastroenterol. 2006;101: Loftus. Gastroenterology. 2004;126:

5 Etiologic Theories in Inflammatory Bowel Disease Genetic Predisposition IBD Mucosal Immune System (Immuno-regulatory Defect) Environmental Triggers (Lumenal Bacteria, Infection)

6 NOD2 and Intra- Cellular Bacteria CD14 LPS MD2 TLR-4 CARD CARD NOD2 PGN LRR MyD88 IRAK RICK/Rip2 NIK TRAF6 ECSIT IKK Smallest unit of PGN muramyl dipeptide IκB NF-κB NF-κB Pro-inflammatory gene expression

7 Key Inflammatory Mediators in Crohn s Disease Antigen APC cell Activated macrophage TNF-α APC cell IL-12 IFN-γ CD4 T cell Activated T cell Th1 cell TNF-α

8 Lumenal Bacteria Stimulate Immune-Mediated Colitis No Bacteria No Immune Activation No Colitis Mice Bacteria IL-2 - / - IL-10 - / - TCRα - / - CD 3 E 26 TG SAMP1/yit DSS CD 45 RB hi SCID Rats B 27 /β2m TG Indomethacin Guinea pigs Carrageenan IL-1β TNFα TNFα IFNγ Colitis TH 1

9 Cause of PSC and IBD: Patient Perspective Bad genes (my parents; will I give it to my children?) Environment (bad food) Environment (medicine, tobacco) Don t Much Care

10 Don t really know Common Ground We re both here to get patients better

11 Differing Points of View: Overview Cause of PSC/IBD Prescription Medicines Alternative Medicines Diet Internet and Information about PSC/IBD

12 Step-up vs Top-down Approach Step-up approach Biologics (TNF Antagonists) Immunosuppressives Corticosteroids Top-down approach 5-Aminosalicylates and Antibiotics

13 Long-term Maintenance of Remission in CD Week Infliximab 5 mg/kg (ACCENT I) Adalimumab 40 mg EOW (CHARM) Certolizumab 400 mg 4-weekly (PRECiSE 2) Placebo Percent of Patients N = 113 N = 172 N = 215 Remission (CDAI<150) Hanauer et al. Lancet. 2002;359:1541. Colombel JF, et al. Gastroenterology. 2007;132(1): Schreiber S, et al. Presented at UEGW 2005.

14 But is it safe?

15 Paths Meet Keeping one another informed of latest progress Open-mindedness of weighing benefits and risks Hippocratic Oath to do no harm vs. giving something a shot because it might work Individualize Clinical trials....

16 Differing Points of View: Overview Cause of PSC/IBD Prescription Medicines Alternative Medicines Diet Internet and Information about PSC/IBD

17 CAM: Physician s Perspective If it hasn t been subjected to a doubleblind, placebo-controlled, double-dummy randomized trial with concealed allotment, then I m not interested. It s too soon to tell

18 But is it safe?

19 CAM s: Patients Perspective Natural and safe Probiotics Prebiotics Herbal medications Vitamins Acupuncture Supplements Yoga Other....

20 Paths Meet Keeping one another informed of latest progress Open-mindedness Hippocratic oath to do no harm vs. giving something a shot because it might work Clinical trials....

21 Overview Cause of PSC/IBD Prescription Medicines Alternative Medicines Diet Internet and Information about PSC/IBD

22 Diet in IBD: Physician s Perspective It s about the plumbing Avoidance of uncooked fruits and vegetables in patients with stricturing disease Liquid diet with partial obstruction General principles of micronutrient absorption I dunno Impossibility of dietary trials It s too soon to tell

23 Diet: Patient Perspective Near primary or primary importance Something to take control of Success with manipulation Specific Carbohydrate Diet (SCD)

24 Overview Cause of PSC/IBD Prescription Medicines Alternative Medicines Diet Internet and Information about PSC/IBD

25 Avail 1996 Avail 2004

26 On the fly data. Unpublished Italian study found that taking lithium seemed to slow progression of ALS. 34 patients from the website solicited lithium Rx from their doctors and started taking it. Up to 109 members now. And now track their progress with the data tools on the website. Is this good for people for whom the pace of traditional science is too slow to help them? Even it s half true, it s still groundbreaking. I don t want to wait for something else. I don t have time to wait.

27 NOPE Physician Advocacy of the Internet? Only 4% of patients were ever advised by a physician to get medical information from the Web (JAMA Conner Oct 18, 2000) Only 39% of physicians see the internet as a valuable health information resource for consumers (Reents et al Neither the growth in patient use of the Web as an information resource nor a significant volume of web content is being driven by physicians

28 One Physician s Practical pscpartners.org Approach ccfa.org site has spot on information crohnsandme.com web site also Discuss findings on the web with physician before changing approach to therapy Grain of salt for everything on the web (especially chat rooms)

29 Thank you

D2 inhibits TLR2- initiated 12p40 transcription (-) TLR2 PGN MDP. MyD88 IRAK ECSIT TRAF6 NIK. Smallest unit of PGN muramyl dipeptide IKK.

D2 inhibits TLR2- initiated 12p40 transcription (-) TLR2 PGN MDP. MyD88 IRAK ECSIT TRAF6 NIK. Smallest unit of PGN muramyl dipeptide IKK. D2 inhibits TLR2- initiated 12p40 transcription CARD CARD NOD2 LRR RICK/Rip2 NIK MDP TRAF6 PGN TLR2 MyD88 IRAK ECSIT (-) IKK Smallest unit of PGN muramyl dipeptide IκB NF-κB atanabe et al, 2004 NF-κB IL-12p40

More information

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD

How do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly

More information

Severe IBD: What to Do When Anti- TNFs Don t Work?

Severe IBD: What to Do When Anti- TNFs Don t Work? Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and

More information

Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease

Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,

More information

Immunogenicity of Biologic Agents and How to Prevent Sensitization

Immunogenicity of Biologic Agents and How to Prevent Sensitization Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning

More information

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida

Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence

More information

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic

Perianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification

More information

Medical Therapy for Pediatric IBD: Efficacy and Safety

Medical Therapy for Pediatric IBD: Efficacy and Safety Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission

More information

The Best of IBD at UEGW (Crohn s)

The Best of IBD at UEGW (Crohn s) The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best

More information

Emerging Therapies in IBD 2006

Emerging Therapies in IBD 2006 Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic

More information

Efficacy and Safety of Treatment for Pediatric IBD

Efficacy and Safety of Treatment for Pediatric IBD Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,

More information

Oxford Inflammatory Bowel Disease MasterClass. What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France

Oxford Inflammatory Bowel Disease MasterClass. What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France Oxford Inflammatory Bowel Disease MasterClass What is early IBD? Prof. Laurent Peyrin-Biroulet Head, IBD Unit Nancy University Hospital, France Disclosures Consulting and/or lecture fees from Merck, Abbott,

More information

Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union

Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,

More information

Innate immune regulation of T-helper (Th) cell homeostasis in the intestine

Innate immune regulation of T-helper (Th) cell homeostasis in the intestine Innate immune regulation of T-helper (Th) cell homeostasis in the intestine Masayuki Fukata, MD, Ph.D. Research Scientist II Division of Gastroenterology, Department of Medicine, F. Widjaja Foundation,

More information

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center

Beyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features

More information

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD

An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University

More information

Speaker Introduction

Speaker Introduction Speaker Introduction Stephen B. Hanauer, MD Professor of Medicine and Clinical Pharmacology University of Chicago Pritzker School of Medicine Chief of Gastroenterology, Hepatology, and Nutrition University

More information

Recent Advances in the Management of Refractory IBD

Recent Advances in the Management of Refractory IBD Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline

More information

Ali Keshavarzian MD Rush University Medical Center

Ali Keshavarzian MD Rush University Medical Center Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting

More information

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital

New treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.

More information

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease

Azathioprine for Induction and Maintenance of Remission in Crohn s Disease Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and

More information

INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL

INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL INFLIXIMAB FOR PREVENTION OF POST-OPERATIVE CROHN S DISEASE RECURRENCE: THE PREVENT TRIAL A. Hillary Steinhart, MD MSc FRCP(C) Medical Lead, Mount Sinai Hospital IBD Centre Professor of Medicine University

More information

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy

Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment

More information

Personalized Medicine in IBD

Personalized Medicine in IBD Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016

More information

Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online Support Group.

Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online Support Group. Welcome to Week 2 of the Crohn s & Colitis Foundation of America (CCFA) Online. Last week s material consisted of an overview of inflammatory bowel diseases (IBD), specifically Crohn s disease and ulcerative

More information

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town

Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease Management in South Africa in 2016 Pharmaceutical Care Management Association Dr David Epstein Vincent Pallotti Hospital and University of Cape Town Inflammatory Bowel Disease

More information

Of Treatment For Inflammatory Bowel Diseases

Of Treatment For Inflammatory Bowel Diseases Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock

More information

How to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009

How to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009 How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco

More information

Garrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor

Garrick Brown, MD. Digestive Health Specialists Tacoma Gig Harbor Garrick Brown, MD Digestive Health Specialists Tacoma Gig Harbor Today s Objectives Define IBD, its potential causes and diagnosis Discuss management and treatment Discuss complementary and alternative

More information

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD

IBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and

More information

Crohn's Disease. The What, When, and Why of Treatment

Crohn's Disease. The What, When, and Why of Treatment Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University

More information

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10

Treatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10 Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality

More information

UNDERSTANDING CROHN S DISEASE

UNDERSTANDING CROHN S DISEASE UNDERSTANDING CROHN S DISEASE START YOUR JOURNEY TOWARD UNDERSTANDING INFLAMMATORY BOWEL DISEASE CONTENTS INTRODUCTION 4 WHAT IS CROHN S DISEASE? 6 Symptoms of Crohn s disease 6 WHAT CAUSES CROHN S DISEASE?

More information

Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases

Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven

More information

Newly Recognized Components of the Innate Immune System

Newly Recognized Components of the Innate Immune System Newly Recognized Components of the Innate Immune System NOD Proteins: Intracellular Peptidoglycan Sensors NOD-1 NOD-2 Nod Protein LRR; Ligand Recognition CARD RICK I-κB p50 p65 NF-κB Polymorphisms in Nod-2

More information

Intestinal Microbiota in Health and Disease

Intestinal Microbiota in Health and Disease Intestinal Microbiota in Health and Disease February 27, 2015 Master s Course in Gastroenterology Prof. Kathy McCoy 1 Overview Overview of Gut Microbiota Microbiota in Health Microbiota in Disease 2 Gut

More information

How to use infliximab?

How to use infliximab? How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!

More information

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014

Anne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014 Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn

More information

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD

Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of

More information

Emerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD

Emerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)

More information

Withdrawal of drug therapy in patients with quiescent Crohn s disease

Withdrawal of drug therapy in patients with quiescent Crohn s disease Withdrawal of drug therapy in patients with quiescent Crohn s disease DR. JEAN-FRÉDÉRIC COLOMBEL DIRECTOR OF THE IBD CENTER, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NEW YORK, USA Withdrawal of drug therapy

More information

CCFA. Crohns Disease vs UC: What is the best treatment for me? November

CCFA. Crohns Disease vs UC: What is the best treatment for me? November CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York

More information

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation?

Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Crohn s Disease: Should We Treat Based on Symptoms or Based on Objective Markers of Inflammation? Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic

More information

Mono or Combination Therapy with. Individualized Approach

Mono or Combination Therapy with. Individualized Approach Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago

More information

Positioning New Therapies

Positioning New Therapies Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed

More information

Indications for use of Infliximab

Indications for use of Infliximab Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of

More information

Join the conversation at #GIFORUMCCFA

Join the conversation at #GIFORUMCCFA 1 Join the conversation at #GIFORUMCCFA 2 Disclosures In accordance with the ACCME Standards for Commercial Support of CME, the speakers for this course have been asked to disclose to participants the

More information

Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball

Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:

More information

Treatment of Pediatric IBD: What is Different?

Treatment of Pediatric IBD: What is Different? Treatment of Pediatric IBD: What is Different? January 13, 2017 Michael Kappelman MD, MPH University of North Carolina at Chapel Hill Overview Is Pediatric IBD the same disease? Treatment considerations

More information

Faecalibacterium prausnitzii

Faecalibacterium prausnitzii Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients PNAS 105(43): 16731-16736, 2008. Speaker: Ming-Cheng Chen Advisor:

More information

September 12, 2015 Millie D. Long MD, MPH, FACG

September 12, 2015 Millie D. Long MD, MPH, FACG Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn

More information

The future of IBD therapeutic research

The future of IBD therapeutic research The future of IBD therapeutic research Jean-Frederic Colombel, MD Director Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine, Mount Sinai Hospital New York J-F Colombel has served

More information

Chronic Granulomatous Disease Managing GI Issues

Chronic Granulomatous Disease Managing GI Issues Chronic Granulomatous Disease Managing GI Issues N I C H O L A S H A R T O G, M D D i r e c t o r o f P e d i a t r i c / A d u l t P r i m a r y I m m u n o d e f i c i e n c y C l i n i c A s s i s t

More information

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD

5/2/2018 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD 5/2/218 SHOULD DEEP REMISSION BE A TREATMENT GOAL? YES! Disclosures: R. Balfour Sartor, MD Grant support for preclinical studies: Janssen, Gusto Global, Vedanta, Artizan BALFOUR SARTOR, MD DISTINGUISHED

More information

Percent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =

Percent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N = Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence

More information

Management of Refractory Crohn s Disease

Management of Refractory Crohn s Disease Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium infliximab 100mg powder for intravenous infusion (Remicade ) No. (364/07) Schering-Plough UK Ltd 6 April 2007 The Scottish Medicines Consortium (SMC) has completed its assessment

More information

Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)

Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration

More information

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants

IBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I

More information

New treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy

New treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*

More information

U of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12

U of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12 A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,

More information

Hot Topics In Nutrition & IBD January 6, Kate Vance, RD Wael N. Sayej, MD

Hot Topics In Nutrition & IBD January 6, Kate Vance, RD Wael N. Sayej, MD Hot Topics In Nutrition & IBD January 6, 2018 Kate Vance, RD Wael N. Sayej, MD Nutrients of Focus Calories Calcium Vitamin D Iron Nutritional Treatment in IBD Improve nutritional status As primary therapy

More information

Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center

Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center Laurie S. Conklin, M.D. Inflammatory Bowel Disease Program Children s National Medical Center CROHN S DISEASE Patchy inflammation Mouth to anus involvement Full-thickness inflammation Variable involvement

More information

Which is the Safest Strategy to Treat Moderate to Severe IBD?

Which is the Safest Strategy to Treat Moderate to Severe IBD? Which is the Safest Strategy to Treat Moderate to Severe IBD? David G. Binion, M.D. Co-Director, Inflammatory Bowel Disease Center Director, Translational Inflammatory Bowel Disease Research Visiting Professor

More information

BEYOND MOLECULAR BIOLOGY: IMPROVING QUALITY OF LIFE IN PATIENTS WITH CROHN S DISEASE. Stephen B. Hanauer, MD*

BEYOND MOLECULAR BIOLOGY: IMPROVING QUALITY OF LIFE IN PATIENTS WITH CROHN S DISEASE. Stephen B. Hanauer, MD* BEYOND MOLECULAR BIOLOGY: IMPROVING QUALITY OF LIFE IN PATIENTS WITH CROHN S DISEASE Stephen B. Hanauer, MD* ABSTRACT *Professor of Medicine and Clinical Pharmacology; Chief, Section of Gastroenterology,

More information

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College

Biologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained

More information

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium

Predicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight

More information

Is there an anti-inflammatory diet in IBD?

Is there an anti-inflammatory diet in IBD? CCFA North Texas Chapter IBD education symposium December 2, 2017, Dallas, TX Is there an anti-inflammatory diet in IBD? Themos Dassopoulos, MD Director, Baylor Scott and White Center for IBD Baylor University

More information

Submitted by xxxxxxxxxxxxxxxxx, xxxxxxxxx RCP and co-ordinated by xxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxxxxxx, Royal Liverpool University Hospital.

Submitted by xxxxxxxxxxxxxxxxx, xxxxxxxxx RCP and co-ordinated by xxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxxxxxx, Royal Liverpool University Hospital. Royal College of Physicians statement on the appraisal of use of tumour necrosis factor alpha (TNF-α) inhibitors (adalimumab, certolizumab pegol and infliximab) and natalizumab for Crohn's disease Submitted

More information

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease

Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier

More information

CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM

CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission

More information

Crohn's Disease. The What, When, and Why of Treatment

Crohn's Disease. The What, When, and Why of Treatment Crohn's Disease The What, When, and Why of Treatment Sunanda Kane, MD, FACG Professor of Medicine Department of Gastroenterology and Hepatology Mayo Clinic Rochester, MN In my lecture today, I will be

More information

Moderately to severely active ulcerative colitis

Moderately to severely active ulcerative colitis Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients

More information

Drug Level Monitoring in IBD. Objectives

Drug Level Monitoring in IBD. Objectives Drug Level Monitoring in IBD Corey A. Siegel, MD, MS Director, Dartmouth-Hitchcock IBD Center Associate Professor of Medicine, Geisel School of Medicine at Dartmouth Objectives Review non-biologic drug

More information

Immunology, Faculty of Medicine University of Bari, Bari (Italy) Proprietà benefiche di latte, vino e olio extra vergine di oliva

Immunology, Faculty of Medicine University of Bari, Bari (Italy) Proprietà benefiche di latte, vino e olio extra vergine di oliva Immunology, Faculty of Medicine University of Bari, Bari (Italy) Proprietà benefiche di latte, vino e olio extra vergine di oliva Professor Emilio Jirillo basketball court (about 400 m 2 ) mucosa-associated

More information

John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah

John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review

More information

PD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc. Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Konservative Behandlungsmöglichkeiten?

PD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc. Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Konservative Behandlungsmöglichkeiten? PD Dr. med. R. Wiest / Dr. med. P. Juillerat, MSc Donnerstag 18 ten Oktober 2012 UPDATE PROKTOLOGIE: Fisteln bei M. Crohn : Konservative Behandlungsmöglichkeiten? INTERDISZIPLINÄRE VISZERALE CHIRURGIE

More information

Accepted Manuscript. Frank I. Scott, Siddharth Singh. S (19) DOI: Reference: YJCGH 56282

Accepted Manuscript. Frank I. Scott, Siddharth Singh. S (19) DOI:   Reference: YJCGH 56282 Accepted Manuscript Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win Frank I. Scott, Siddharth Singh PII: S1542-3565(19)30020-5

More information

Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease

Agenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4

More information

Genetic and Environmental Risks for IBD

Genetic and Environmental Risks for IBD Genetic and Environmental Risks for IBD CCFA April 26, 2014 Presented by: Name goes here April 30, 2014 TheoTheodore 1 Genetic and Environmental Risks for IBD Theodore M. Bayless, M.D. Director Emeritus

More information

Innate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin

Innate Immunity. Chapter 3. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples. Antimicrobial peptide psoriasin Chapter Know Differences and Provide Examples Innate Immunity kin and Epithelial Barriers Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive Immunity

More information

Genetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD

Genetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD Advances in the Pathogenesis of IBD: Genetics Leads to Function Pathogenesis of IBD Environmental Factors Microbes Scott Plevy, MD Associate Professor of Medicine, Microbiology & Immunology UNC School

More information

There is no single IBD diet

There is no single IBD diet Nutrition and IBD There is no single IBD diet Nutrition plays an important role in health, during times of IBD disease activity as well as during remission. Although diet does not cause or cure IBD, the

More information

New and Future Adhesion Molecule Based Therapies in IBD

New and Future Adhesion Molecule Based Therapies in IBD New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada

More information

Are Biologicals Safe Enough?

Are Biologicals Safe Enough? Are Biologicals Safe Enough? Dr Anne Duggan Director of Gastroenterology, John Hunter Hospital, Hunter New England Area Health Service (HNEAHS) Conjoint A/Professor, University of Newcastle, Australia

More information

Guide to Gastroenterology Biological Therapeutic Drug Monitoring Pathway (TDM)

Guide to Gastroenterology Biological Therapeutic Drug Monitoring Pathway (TDM) Guide to Gastroenterology Biological Therapeutic Drug Monitoring Pathway (TDM) Author: Responsible Lead Consultants: Endorsing Body: Implementation Date: 01/08/2018 Version Number: 1.0 Review Date: 01/08/2020

More information

Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.

Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab

More information

Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352

Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352 Vedolizumab for treating moderately to severely erely active Crohn's disease after prior therapy Technology appraisal guidance Published: 26 August 2015 nice.org.uk/guidance/ta352 NICE 2017. All rights

More information

Mucosal healing: does it really matter?

Mucosal healing: does it really matter? Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does

More information

CROHN S DISEASE AND ULCERATIVE COLITIS

CROHN S DISEASE AND ULCERATIVE COLITIS Slide 1 CROHN S DISEASE AND ULCERATIVE COLITIS Slide 2 Slide 3 Crohn s Inflammation in the GI tract but usually in the lower part of the small intestines and the colon. Inflammation occur between healthy

More information

Vedolizumab: policing leukocyte traffic

Vedolizumab: policing leukocyte traffic Oxford Inflammatory Bowel Disease MasterClass Vedolizumab: policing leukocyte traffic Dr Brian Feagan, London, Canada Vedolizumab : Policing Lymphocyte Traficking Brian G. Feagan Professor of Medicine,

More information

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists

Disclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic

More information

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium

Mucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract

More information

2nd Nottingham IBD Masterclass, 2017

2nd Nottingham IBD Masterclass, 2017 2nd Nottingham IBD Masterclass, 217 Positioning IL12/IL23 blockade in the Crohn s disease treatment algorithm Prof James Lindsay, Consultant Gastroenterologist, Barts Health NHS Trust Professor in Inflammatory

More information

My Child Has Inflammatory Bowel Disease : Why? What now? What s next?

My Child Has Inflammatory Bowel Disease : Why? What now? What s next? My Child Has Inflammatory Bowel Disease : Why? What now? What s next? George M. Zacur, M.D., M.S. Clinical Assistant Professor Department of Pediatrics and Communicable Diseases Division of Gastroenterology

More information

NOD2 Activation promotes anti-inflammatory activity of human Umbilical cord blood MSCs against Inflammatory bowel disease

NOD2 Activation promotes anti-inflammatory activity of human Umbilical cord blood MSCs against Inflammatory bowel disease NOD2 Activation promotes anti-inflammatory activity of human Umbilical cord blood MSCs against Inflammatory bowel disease Prof. Kyung-Sun Kang, DVM, PhD. Adult Stem Cell Research Center Seoul National

More information

Innate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin

Innate Immunity. Connection Between Innate and Adaptive Immunity. Know Differences and Provide Examples Chapter 3. Antimicrobial peptide psoriasin Know Differences and Provide Examples Chapter * Innate Immunity * kin and Epithelial Barriers * Antimicrobial peptide psoriasin -Activity against Gram (-) E. coli Connection Between Innate and Adaptive

More information

Update in Pediatric IBD: 2018

Update in Pediatric IBD: 2018 Update in Pediatric IBD: 2018 Jeffrey S. Hyams, MD Head, Division of Digestive Diseases, Hepatology and Nutrition Mandell-Braunstein Family Endowed Chair in Pediatric Inflammatory Bowel Disease Connecticut

More information